Loading
Heart Failure NYHA Class III / Heart Failure NYHA Class Ii / Barostim System · Interventional Study
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an active interventional trial (BENEFIT-HF, NCT07232030) testing Baroreflex Activation Therapy (BAT) via the Barostim System in heart failure patients with reduced ejection fraction. No results are reported in this record; the study is enrolling by invitation and has not yet completed 24-month follow-up or the 180-day safety window.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III; age from 18 Years. Intervention: Device Arm. Compared with: Control Arm — Active Comparator. n = 2,500. 8 sites: United States.
This is a registry record for an active interventional trial (BENEFIT-HF, NCT07232030) testing Baroreflex Activation Therapy (BAT) via the Barostim System in heart failure patients with reduced ejection fraction. No results are reported in this record; the study is enrolling by invitation and has not yet completed 24-month follow-up or the 180-day safety window.
No interim analyses, efficacy data, or safety outcomes reported
The source did not state who this applies to in practice.
This is a clinical trial registry record describing a planned interventional study with no results reported; enrollment is ongoing and primary endpoints have not yet been assessed.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07232030). This is a study registration, not published results. Lead sponsor: CVRx, Inc.. Recruitment status: ENROLLING_BY_INVITATION. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 2500 participants (ESTIMATED). Conditions: Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III. Interventions: DEVICE: Barostim System; OTHER: Usual care medical management. Primary outcome measures: Primary Effectiveness Endpoint , Through 24-months follow-up; Primary Safety Endpoint , Within 180 days of the device implant. Brief summary: The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.